Rainbow Coral Corp. today told investors that it is considering new funding opportunities with promise in order to expand in the $232 billion personalized medicine market.
The company is pushing forward with its aggressive expansion strategy for this year and is already poised for rapid growth. The company recently signed a joint venture agreement with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective, and more convenient than ever before, and is currently in negotiations to partner with an emerging innovator in the transdermal delivery sector, as well. Last month, RBCC's joint venture partner, Nano3D BioSciences, announced a distribution agreement with St. Louis-based scientific products distributor MIDSCI to sell its revolutionary BioAssembler product line in the multi-billion-dollar U.S biotechnology market.
"Our company is now well-positioned in a robust marketplace, and new funding opportunities are opening up for us every day," said RBCC CEO Patrick Brown. "We're carefully considering our options in order to ensure that we're able to accomplish the goals that we've set for ourselves this year."
Focused on expanding its marketing and development efforts, RBCC is fully committed to capitalizing on the unprecedented rise of the biotechnology sector.
For more information on RBCC's partnership with n3D and other biotech initiatives, visit rainbowbiosciences.com/investors.html.
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net